Previously treated patients with metastatic pancreatic adenocarcinoma were randomly assigned at a ratio of @:@ to two doses of Cy/GVAX followed by four doses of CRS-@ ( arm A ) or six doses of Cy/GVAX ( arm B ) every @ weeks .